Cingulate (CING) to Release Quarterly Earnings on Monday

Cingulate (NASDAQ:CING) is expected to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($1.48) per share for the quarter.

Cingulate Stock Performance

NASDAQ CING opened at $4.35 on Monday. Cingulate has a 12 month low of $1.80 and a 12 month high of $20.83. The company’s 50 day moving average is $4.28 and its two-hundred day moving average is $4.45.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CING shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Cingulate in a research note on Thursday, March 6th. Roth Capital upgraded Cingulate to a “strong-buy” rating in a research report on Friday, January 10th. Finally, Roth Mkm initiated coverage on Cingulate in a report on Friday, January 10th. They issued a “buy” rating and a $12.00 price target on the stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.